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Background: Major depressive disorder (MDD) may be present in 10%–20% of patients in medical settings. Routine
depression screening is sometimes recommended to improve depression management. However, studies of the
diagnostic accuracy of depression screening tools have typically used data-driven, exploratory methods to select
optimal cutoffs. Often, these studies report results from a small range of cutoff points around whatever cutoff score is
most accurate in that given study. When published data are combined in meta-analyses, estimates of accuracy for
different cutoff points may be based on data from different studies, rather than data from all studies for each possible
cutoff point. As a result, traditional meta-analyses may generate exaggerated estimates of accuracy. Individual patient
data (IPD) meta-analyses can address this problem by synthesizing data from all studies for each cutoff score to obtain
diagnostic accuracy estimates. The nine-item Patient Health Questionnaire-9 (PHQ-9) and the shorter PHQ-2 and PHQ-8
are commonly recommended for depression screening. Thus, the primary objectives of our IPD meta-analyses are to
determine the diagnostic accuracy of the PHQ-9, PHQ-8, and PHQ-2 to detect MDD among adults across all potentially
relevant cutoff scores. Secondary analyses involve assessing accuracy accounting for patient factors that may influence
accuracy (age, sex, medical comorbidity).
Methods/design: Data sources will include MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, PsycINFO, and
Web of Science. We will include studies that included a Diagnostic and Statistical Manual or International Classification
of Diseases diagnosis of MDD based on a validated structured or semi-structured clinical interview administered within
2 weeks of the administration of the PHQ. Two reviewers will independently screen titles and abstracts, perform full article
review, and extract study data. Disagreements will be resolved by consensus. Risk of bias will be assessed with the Quality
Assessment of Diagnostic Accuracy Studies-2 tool. Bivariate random-effects meta-analysis will be conducted for the full
range of plausible cutoff values.
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Discussion: The proposed IPD meta-analyses will allow us to obtain estimates of the diagnostic accuracy of the PHQ-9,
PHQ-8, and PHQ-2.
Systematic review registration: PROSPERO CRD42014010673
Keywords: Patient health questionnaire, PHQ-9, PHQ-8, PHQ-2, Depression, Screening, Diagnostic test accuracy,
Systematic review, Individual patient data meta-analysisBackground
Major depressive disorder (MDD) is a chronic, disabling
condition that is present in 5%–10% of primary care
patients [1,2] and 10%–20% of patients with chronic
medical conditions [3]. Unidentified and inadequately
treated depression has a major impact on overall health
and is a robust indicator of poor prognosis, above and
beyond other health risk factors [4]. Globally, depression
accounts for more years of healthy life lost than any other
medical condition [5-8].
Delivery of depression care, however, is often haphazard,
and misdiagnosis is common. Physicians may fail to recog-
nize as many as half of all patients with depression [9],
and most patients with depression do not receive min-
imally adequate care [10,11]. At the same time, there is
a high rate of overdiagnosis and overtreatment, and the
majority of patients who are treated for depression do
not meet diagnostic criteria [12,13]. In specialty medicine
settings, rates of depression are even higher than in
primary care, but health care teams in specialty settings
typically have less specific training on recognizing or
treating depression than providers of primary care [3].
Thus, improving depression care is a priority [14].
Routine depression screening, which involves the use of
self-report questionnaires to identify patients with unre-
cognized MDD who have not been identified as at risk
for depression, has been proposed as a way to improve
depression identification and management [15,16]. Rec-
ommendations, policy, and implementation, however, are
inconsistent. Prior to 2002, no major guidelines recom-
mended depression screening. Then, in 2002, the United
States Preventive Services Task Force (USPSTF) recom-
mended routine depression screening in primary care set-
tings with staff-assisted depression care programs in place
to ensure accurate diagnosis, effective treatment, and
follow-up [17]. In 2005, the Canadian Task Force on Pre-
ventive Health Care (CTFPHC) issued a similar guideline
[15], and in 2009, the USPSTF reiterated its recommenda-
tion [18,19]. However, the USPSTF recommendation has
been criticized as based on speculation that depression
screening may benefit patients when high-quality care is
provided, but not on direct evidence from randomized
controlled trials (RCTs) [20,21]. Consistent with this, in
2010, the UK National Screening Committee determined
that there was no evidence that depression screeningwould reduce the number of patients with depression or
improve depression symptoms [22], and the UK National
Institute for Health and Clinical Excellence recommended
against routine depression screening [2]. In 2013, the
CTFPHC reconsidered its earlier guideline and also
recommended against screening adults for depression
in primary care settings [23]. There are numerous rec-
ommendations to screen for depression in speciality
medicine settings [24-31], but none is based on evidence
of benefit from RCTs, and the wisdom of investing health
care resources for screening in these settings without
evidence has been questioned [32-36].
In its recent decision to recommend against depression
screening in primary care, the CTFPHC concluded that
although depression screening may frequently occur in
clinical practice, no properly designed RCTs of depres-
sion screening have demonstrated benefit or how to
successfully implement a depression screening program
that would reduce the presence of depression. The Task
Force expressed concern that the true diagnostic accuracy
of commonly used depression screening tools is poorly
understood, that existing evidence may overstate what
would occur in actual clinical practice, and that screening
without demonstrated screening tool accuracy would
likely generate a high rate of false positive screens without
improving patient care [23].
In studies on the accuracy of depression screening tools,
patient scores on self-report depression symptom ques-
tionnaires are compared to diagnostic status (MDD versus
no MDD) based on a validated diagnostic interview. Diag-
nostic accuracy is most commonly described in terms of
sensitivity, specificity, positive predictive value, and nega-
tive predictive value. In depression screening, sensitivity is
the probability that a screening test will correctly identify
patients with MDD, whereas specificity is the probability
that the test will correctly classify patients without MDD
as non-cases [37]. Sensitivity and specificity are generally
regarded as intrinsic characteristics of a test and inde-
pendent of prevalence [38,39]. Studies of diagnostic accur-
acy typically use receiver operating characteristic (ROC)
curve analysis, by which sensitivity and specificity associ-
ated with all possible cutoff scores are calculated and plot-
ted [40,41]. From the ROC, an optimal cutoff score is
chosen which balances the trade-off between increases in
sensitivity and decreases in specificity, and vice versa.
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reported, predictive values are more clinically relevant.
The positive predictive value of a screening tool refers to
the probability that a patient with a positive screen will
have the condition, whereas negative predictive value is
the probability that a negative test accurately rules out
the condition. Positive and negative predictive values
depend on both test accuracy and prevalence [42]. When
screening is done in clinical practice, the relevant infor-
mation for the health care provider is the probability of
the patient with positive (and negative) screens having
the corresponding condition (e.g., MDD in depression
screening).
There are several important shortcomings in existing
evidence on depression screening tool accuracy. Most
existing studies have been conducted in samples too
small to precisely estimate accuracy and have selectively
published accuracy results from high-performing cutoffs,
but not from other cutoffs, even when the other cutoffs
are considered standard [32,36]. Meta-analyses can over-
come problems associated with small sample sizes but
are unbiased only if accuracy data for all relevant studies
and cutoff scores are included. Some meta-analyses
[43,44] have focused on results of primary studies for a
standard cutoff, if published, but have substituted data
from other cutoffs for large numbers of studies that did
not report results for the standard cutoff, presumably
because the standard cutoff performed poorly in those
studies. Other meta-analyses [45-47] have examined results
from multiple cutoffs but have similarly been limited to
using published accuracy outcomes for each cutoff. The
limitations of this method are highlighted by a 2012
meta-analysis of the Patient Health Questionnaire (PHQ-9)
[45], a commonly used screening tool [27,48-51]. In that
meta-analysis, estimates of sensitivity actually improved as
the cutoff increased (i.e., as more severe symptoms were
required for detecting cases), which would be mathematic-
ally impossible if complete data from all studies were
available and analyzed as a single data set.
In addition to selective reporting, inclusion in diagnostic
accuracy studies of patients who are already treated and
would not be screened in clinical practice may bias results
in primary studies and meta-analyses. One study found
that >95% of existing diagnostic accuracy studies of
depression screening tools have included already-treated
patients, thus exaggerating the estimated number of previ-
ously unidentified patients who would be detected and
likely biasing estimates of accuracy [16].
Finally, individual studies have sample sizes too small to
evaluate individual risk characteristics that may influence
diagnostic accuracy, and thus, traditional meta-analyses
have not been able to address them either. As described
by the CTFPHC [23], accuracy analyses based on individ-
ual risk characteristics (e.g., age, sex, medical comorbidity)that likely influence the optimal screening cutoff and
accuracy are needed.
Individual patient data (IPD) meta-analysis [52] involves
using actual patient data obtained from researchers who
conducted primary studies, rather than summary results
from published or unpublished study reports. The general
approach of an IPD meta-analysis in terms of defining
a research question, establishing study inclusion and
exclusion criteria, identifying and screening studies, and
analyzing data does not differ from a traditional meta-
analysis [53]. IPD meta-analyses are resource intensive
in that they require substantial time to identify and
obtain original data, clarify data-related issues with data
providers, and generate a consistent data format across
studies [52-54]. When implemented effectively, IPD meta-
analyses have particular benefits in addressing limitations
in published information or where subgroup analyses
are needed, but not possible from study-level data avail-
able in original reports, as is the case with depression
screening accuracy studies. In the context of evaluating
the diagnostic accuracy of depression screening tools,
IPD meta-analysis has three major advantages compared
to traditional meta-analyses. First, IPD meta-analysis
can address bias from the selective publication of well-
performing cutoff thresholds from small studies since
accuracy can be evaluated across all relevant cutoff
scores. Second, IPD meta-analysis allows the exclusion
of already-treated patients, for whom the tool would
not be used to screen for unidentified depression, as
treatment status is often available in primary datasets.
Third, IPD meta-analysis with large numbers of patients
and large numbers of MDD cases allows the incorporation
of individual risk factors for depression (e.g., age, sex,
medical comorbidity) and study variables (e.g., study
setting, risk of bias factors, funding source) that may
influence cutoff selection, accuracy, and clinical decision-
making.
The nine-item PHQ-9 [55] and the PHQ-2 [56] and
PHQ-8 [57], which are two-item and eight-item subsets
of the nine items in the PHQ-9, are commonly recom-
mended for depression screening in clinical and research
settings [27,48-51]. Thus, the primary objective is to
conduct IPD meta-analyses to determine the diagnostic
accuracy of the PHQ-9, PHQ-8, and PHQ-2 to detect
MDD among adults. A secondary objective is to assess
diagnostic accuracy accounting for age, sex, and medical
comorbidity, which may influence accuracy.
Methods/design
This systematic review has been funded by the Canadian
Institutes for Health Research (Funding Reference Num-
ber KRS-134297). The protocol has been registered in
the PROSPERO prospective register of systematic reviews
(CRD42014010673). Ethical approval has been obtained
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Hospital in Montreal.
Our IPD meta-analysis has been designed and will be
conducted in accordance with best-practice standards as
elaborated in the Cochrane Handbook for Systematic
Reviews of Diagnostic Test Accuracy [58] and other key
sources [52,53,59]. Results will be reported in concordance
with the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [60,61]. To con-
duct the meta-analysis, we will seek primary datasets
that allow us to compare PHQ-9 scores to MDD or
major depressive episode (MDE) diagnostic status. Most
primary studies use MDD as the reference standard, but
some may use MDE, which is identical with respect to the
symptoms of depression but does not exclude patients
with psychotic disorders or a history of manic episodes.
We will extract the necessary items from the PHQ-9 to
also evaluate the briefer PHQ-2 and PHQ-8. In addition,
we will include studies with only data from the PHQ-2 or
PHQ-8 in those meta-analyses.
Sources of evidence
Our search strategy was developed by a medical librarian
and peer-reviewed by another medical librarian. We
will search MEDLINE, MEDLINE In-Process & Other
Non-Indexed Citations, PsycINFO, and Web of Science.
The MEDLINE search strategy was validated by testing
against already-identified publications from preliminary
searches (see Appendix 1), and no studies with more
than five MDD cases were missed. The strategy was then
adapted for PsycINFO and Web of Science. We limited
our search strategy to these databases based on research
showing that adding other databases (e.g., EMBASE) when
the MEDLINE search is highly sensitive does not identify
additional eligible studies [62]. The Cochrane Handbook
for Systematic Reviews of Diagnostic Test Accuracy [58]
suggests combining concepts of the index test and the
target conditions, but this was redundant for depression
screening tools as these tests are limited to testing for
depression. Thus, the search strategy for electronic data-
bases was comprised of two concepts: the index test of
interest and studies of screening accuracy. There are no
published search hedges designed specifically for mental
health screening, but several key articles were consulted in
developing search terms [63-65]. Search strategies use a
combination of subject headings, when available in the
database, as well as keywords anywhere in the record. The
search was limited to the year 2000 forward since the
PHQ was first published in 2001 [55]. See Appendix 1
for detailed information on searches. To supplement
electronic searches, we will search reference lists of all
included publications and relevant reviews. In addition,
we will conduct a related articles search for included
papers indexed in MEDLINE using the PubMed “relatedarticles” search feature. We will also contact researchers
who have published on the topic to obtain information
about additional, unpublished studies. Search results will
be initially uploaded into the citation management data-
base RefWorks (RefWorks, RefWorks-COS, Bethesda, MD,
USA) then into the systematic review program DistillerSR
(Evidence Partners, Ottawa, Canada). The DistillerSR
duplication check function will be used to identify cita-
tions retrieved from multiple sources. DistillerSR will
be used to store and track search results and to track
results of the review process.
To identify relevant datasets, we will review articles in
any language. Datasets will be sought for inclusion if they
compare results from the PHQ-9, PHQ-8, or PHQ-2 to
Diagnostic and Statistical Manual (DSM) or International
Classification of Diseases (ICD) criteria for MDD or MDE.
ICD criteria are similar to DSM criteria and generally used
outside of North America. Diagnoses must be based on a
validated structured or semi-structured interview (e.g.,
Structured Clinical Interview for DSM [66], Composite
International Diagnostic Interview [67]) administered
within 2 weeks of the administration of the depression
screening tool, since MDD criteria are for symptoms in
the last 2 weeks. Datasets where some patients were
administered the screening tools within 2 weeks of the
diagnostic interview and some patients were not will be
included if the original data allows us to select patients
administered the diagnostic interview and screening
tools within the 2-week window. Data from studies
where the PHQ is used with patients already known to
have psychiatric diagnoses will be excluded, with the
exception of patients treated for substance and alcohol
abuse for whom depression screening may be consid-
ered. The coding manual for inclusion and exclusion
decisions is shown in Appendix 2.
Two investigators will independently review titles and
abstracts for eligibility. If either reviewer determines that a
study may be eligible based on title or abstract review, then
a full-text article review will be completed. Disagreement
between reviewers after full-text review will be resolved by
consensus, including a third investigator as necessary.
Chance-corrected agreement between reviewers will be
assessed with Cohen’s kappa statistic. Translators will
be consulted to evaluate titles/abstracts and articles for
languages other than those for which team members
are fluent (English, French, Spanish, Dutch, Greek). See
Figure 1 for the preliminary PRISMA flow of studies.
Transfer of data and dataset management
We will contact authors of studies containing datasets that
meet our inclusion criteria to invite them to contribute
primary data for inclusion.
Per our approved ethics protocol, when an investigator
agrees to contribute data, approval for incorporation of
Figure 1 Draft flow diagram of study selection process.
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Committee of the Jewish General Hospital in Montreal,
which will require documentation of ethics approval and
informed patient consent of the primary study. In cases
where documentation of the original ethics approval and
patient consent forms are not retrievable, ethics approval
will be granted if there is other documentation (e.g.,
publications that document ethics approval and patient
consent).
We will ensure that all data that are transferred are
properly de-identified prior to transfer. All individual
patient data that are obtained will be cleaned and coded
to make patient data as uniform as possible across datasets,
then entered into a single STATA database (StataCorp,
College Station, TX). A preliminary codebook has been
developed for coding data from original studies of the
PHQ (see Appendix 3). For each study to be included
in the dataset, two investigators will independently
determine the coding protocol, based on the codebook,
with any discrepancies resolved by consensus. Actual data
coding and transfer from original studies into the IPD
database will be done independently by two supervisedstaff or trainee members of the team, and resulting
datasets will be compared using STATA to identify dis-
crepancies. Data will be stored on password-protected
computers with a well-configured firewall, IDS/IPS, up-
to-date antivirus and antispyware, passwords for logical
access, and a secured backup system.
In addition to obtaining original patient-level data, we
will extract data found in the published articles from the
studies we included. Two authors will cross-check the
published data with the original patient-level data ob-
tained from each dataset, and any inconsistencies will be
discussed with the original authors. Corrections will be
made as necessary.
Quality assessment
We will use the Quality Assessment of Diagnostic Accur-
acy Studies-2 (QUADAS-2) tool [68] to assess risk of
bias factors in primary studies, and these factors will be
included as study-level variables in analyses. QUADAS-2
incorporates assessments of risk of bias across four core
domains: patient selection, the index test, the reference
standard, and the flow and timing of assessments. Two
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discrepancies resolved by consensus.Data analysis
Analyses will estimate sensitivity and specificity, which
will be used to generate estimates of positive predictive
value (PPV) and negative predictive value (NPV), which
are more useful clinically. We will fit a bivariate random-
effects meta-analysis, estimated via Gaussian Hermite
adaptive quadrature, as described in Riley et al. [69], for
the full range of plausible cutoff values. This approach
models sensitivity and specificity simultaneously and
accounts for variation in within-study precision [69].
Data from all primary studies will be analyzed at the same
time using a random-effects model so that sensitivity and
specificity are assumed to vary across studies. This model
will provide us with an overall pooled sensitivity and
specificity and an overall pooled diagnostic odds ratio
for each cutoff. By combining information across a
range of cutoffs, we will be able to construct a pooled
ROC curve and identify the cutoff scores [69]. We will
present the ROC curves from each primary study, as
well as the pooled ROC curve. Optimal cutoffs and the
balance between sensitivity and specificity depend on
the values of test users [70]. We will identify potentially
optimal cutoffs under different scenarios and use these to
generate a nomogram, which is a user-friendly graphical
depiction of PPV and NPV by prevalence (see example in
Figure 2). We will compare results from our IPD meta-
analysis to results using only published data. Specifically,
we will assess whether optimal cutoffs that maximize
combined sensitivity and specificity differ between the
two methods. In addition, we will compare sensitivity
and specificity estimates across cutoffs using the twoFigure 2 Example of a nomogram depicting post-test probability of m
different prevalences and assuming 80% sensitivity and 80% specificmethods with deviations of 5% or more considered to
be outside an acceptable window of difference.
Heterogeneity will be quantified by reporting the esti-
mated variances of the random effects for sensitivity and
specificity, as well as by estimating R. R is the ratio of
the estimated standard deviation of the pooled sensitivity
from the random-effects model to the estimated standard
deviation of the pooled sensitivity from the fixed-effects
model [71].
In secondary analyses, we will adjust estimates of sensi-
tivity and specificity for age (<60 years versus ≥60 years),
sex, and the presence or absence of medical comorbidity.
This will allow an estimation of whether the sensitivity
and specificity calculated based on the optimal cutoff
identified vary according to patient subgroups. Additional
study-level covariates may be examined on an exploratory
basis. Study-level covariates may include study setting and
risk of bias factors described in QUADAS-2. Study setting
will initially be delineated as North America or Europe
versus from other parts of the world, as well as care
setting (e.g., primary care, outpatient specialty care, in-
patient care), but may be adjusted based on available
data. Administration setting will also be coded (e.g., inter-
net, telephone, in person in acute care setting, in person
in outpatient area). QUADAS-2 factors that will be in-
corporated include patient selection factors, blinding of
reference standard to index test results, type of reference
standard (e.g., semi-structured diagnostic interview, struc-
tured diagnostic interview, physician interview), and tim-
ing of administration of index test and reference standard
(e.g., same day, delay of 1 to 7 days, delay of >7 days).
Assessing the influence of patient- and study-level fac-
tors on diagnostic accuracy can easily be accomplished
by including study-, patient- or interaction terms in the
random-effects model described above [69]. For patient-ajor depression as a function of the screening test result for
ity.
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and within-study components, which is achieved by cal-
culating the study-specific average for the between-study
component and the deviation from that average for the
within-study component [69,72]. These analyses take
advantage of the richness of individual patient data.
When analyzed at the patient-level, accounting for cor-
relation between patients from the same study and for
the correlation between sensitivity and specificity via
the random-effects model, they are more powerful to
detect interactions and not vulnerable to ecologic bias
compared to traditional meta-analyses [73-76].
To estimate accuracy parameters taking into consider-
ation patient and setting characteristics, we will build
predictive models that use the score on the screening
questionnaire, as well as age, sex, and other relevant vari-
ables to predict MDD. The variables used will be generally
available (e.g., age, sex, medical comorbidity, medical set-
ting) and chosen a priori, via consultation with specialists
from the research team and the literature. The models will
be evaluated in terms of their calibration (e.g., slope of
linear predictor; are average, low and high predictions
correct?) and discrimination (e.g., c-statistic; are low risk
subjects distinguished from high risk subjects?) [77].
Validation with the same subjects used to develop a
model results in overly optimistic performance. We will
assess internal validation via the bootstrap method,
which has been shown to be preferable to split sample
validation approaches (e.g., developing the model in
half the sample and evaluating it in the other half ) [78].
Although there are advantages to external validation,
given the wide range of study populations that we will be
using, it would be unlikely that there would be another
comparable dataset large enough for validation. Thus,
assessment of internal validity via bootstrapping will allow
us to understand how our model will likely perform in a
clinical setting, and by using the regression coefficients
adjusted for optimism (i.e., the shrinkage estimates), will
maximize actual accuracy. Based on our pilot work, we
anticipate that missing data will be minimal for the vari-
ables of primary interest, and we will impute via multiple
imputation using chained equations [77,79], which allow
us to impute data for both binary and continuous vari-
ables, considering study as a fixed effect in the imputation
model [79]. This will allow us to impute both for variables
missing for entire studies as well those missing more
sporadically.
As sensitivity analyses, we will treat the score as ordinal
and use the methods described by Riley et al. to estimate
pooled sensitivity and specificity across all thresholds sim-
ultaneously [80,81]. In further sensitivity analyses, we will
compare studies included in the IPD meta-analysis and
those not included in terms of sensitivity and specificity.
We will also conduct a sensitivity analysis in which weinclude aggregate summary estimates of sensitivity and
specificity from studies that do not provide individual
patient data in our analyses [69].
Discussion
Depression is a chronic and disabling condition that is
the leading global cause of life years lived with disability
and plays a major role in coping and prognosis among
patients with medical illness [5-8]. However, most patients
with depression do not receive adequate care [10,11].
Screening has been proposed as a solution and is currently
implemented in practice in many settings in a patchwork
fashion. Across national settings, there is a high degree
of inconsistency in recommendations, provincial-level
policies, and actual practice. There is a need for properly
designed, well-conducted trials to determine if depression
screening would benefit patients and, if so, to provide
models for implementation in clinical practice. Major
limitations in existing evidence on the accuracy of depres-
sion screening tools, however, present a major barrier to
conducting high-quality trials and to potentially including
screening as a routine part of clinical practice. The PHQ-9
and briefer versions, the PHQ-2 and PHQ-8, are easily ad-
ministered, commonly used depression screening tools. By
conducting an IPD meta-analyses that address biases in
existing evidence and integrates individual patient charac-
teristics into screening, this study will produce an estimate
of screening accuracy that is not biased by selective cut-
off reporting, that appropriately excludes already-treated
patients from the analysis, and that accounts for patient
variables that may influence screening accuracy.
Appendix 1: Search strategies
MEDLINE (OvidSP)
1. PHQ*.af.
2. patient health questionnaire*.af.
3. 1 or 2
4. Mass Screening/
5. Psychiatric Status Rating Scales/
6. “Predictive Value of Tests”/
7. “Reproducibility of Results”/





13. exp Diagnostic Errors/
14. Mental Disorders/di, pc [Diagnosis, Prevention &
Control]
15. Mood Disorders/di, pc [Diagnosis, Prevention &
Control]
16. Depressive Disorder/di, pc [Diagnosis, Prevention
& Control]
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Prevention & Control]
18. Depression, Postpartum/di, pc [Diagnosis,
Prevention & Control]

























43. 3 and 42
44. limit 43 to yr = “2000-Current”
PsycINFO (OvidSP)
1. PHQ*.af.
2. patient health questionnaire*.af.





























33. 3 and 32
34. Limit 33 to “2000 to current”
Web of Science (Web of Knowledge)
#1: TS = (PHQ* OR “Patient Health Questionnaire*”)
#2: TS = (screen* OR prevalence OR “predictive value*” OR
detect* OR sensitiv* OR valid* OR revalid* OR predict* OR
accura* OR psychometric* OR identif* OR specificit*
OR cutoff* OR “cut off*” OR “cut* score*” OR cutpoint*
OR “cut point*” OR “threshold score*” OR “reference
standard*” OR “reference test*” OR “index test*” OR
“gold standard”)
#1 AND #2
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S,
CPCI-SSH Timespan =2000-2014
Appendix 2: Coding manual
Title/abstract screening
1. Exclude if no original human data or it is a case study.
Exclude if it is clear from the title and abstract that
the article is not an original report of primary data,
but for example a letter, editorial, systematic review
or meta-analysis, or if it is a case series or single case
study. Studies reporting only on animal, cellular, or
genetic data are also excluded. Studies that report re-
sults in conference abstracts are eligible for inclusion.
2. Exclude if study did not involve administration of
the PHQ-9, PHQ-2, or PHQ-8.
Exclude if there is no mention in the title or abstract
of any of these versions of the Patient Health
Questionnaire. Note that the PHQ-4 (depression
and anxiety) includes the PHQ-2.
3. Exclude if there is no assessment of major depression.
Exclude studies if it is clear from the title and abstract
that a clinical interview for depression was not con-
ducted. Only studies that assess adults for a DSM
diagnosis of MDD or ICD diagnosis of a major de-
pressive episode will be included. Studies that include
broader diagnostic categories, such as other depres-
sive (e.g., minor depression, dysthymia) or anxiety
disorders, are eligible for inclusion only if they may
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major depressive episode in the primary data. It is un-
likely that studies can be excluded at the title/abstract
level based on differential diagnosis (e.g., major versus
major +minor depression).
4. Exclude if studies do not use a validated diagnostic
interview to assess major depression.
Only studies that assess adults for a DSM diagnosis
of MDD or ICD diagnosis of a major depressive epi-
sode using a validated structured or semi-structured
diagnostic interview will be included. Examples of val-
idated diagnostic interviews and other assessment
tools that are not validated diagnostic interviews are
listed below. Studies that clearly only used a self-
report questionnaire to classify patients as depressed
are excluded. If studies appear to have conducted a
clinical interview to diagnose depression based on
the title/abstract review, but it is not clear if a vali-
dated diagnostic interview was used, they should
be included for full-text review.
Examples of validated diagnostic interviews:
Composite International Diagnostic Interview (CIDI)
Diagnostic Interview Schedule (DIS)
Diagnostic Interview Schedule for Children (DISC)
Diagnostisches Interview bei psychischen Störungen
im Kindes (Kinder-DIPS)
Mini-International Neuropsychiatric Interview (MINI)
Schedule for Affective Disorders and Schizophrenia
(SADS)
Schedules for Clinical Assessment in Neuropsychiatry
(SCAN)
Structured Clinical Interview for DSM (SCID)
Examples of assessment tools that are not validated
diagnostic interviews:
Any self-report measure completed by patients
Hamilton Depression Rating Scale (HAM-D, HDRS)
Montgomery Asberg Depression Rating Scale (MADRS)
Primary Care Evaluation of Mental Disorders
(PRIME-MD)
WHO Major Depression Inventory
International Diagnostic Checklist for ICD-10
5. Exclude if PHQ and diagnostic interview are not
administered within 2 weeks of each other.
Studies are excluded if it is clear based on the title and
abstract that the PHQ and diagnostic interview were
not administered within 2 weeks of one another, such
as in a longitudinal study that administered one at one
time point and the other at a different time point.
6. Exclude if sample selection is based on the presence
of distress or depression.
Studies of patients who are pre-selected as possibly
distressed or depressed (e.g., based on clinician’s judg-
ment or screening instrument cutoff ) prior to ad-
ministration of the study screening tool and diagnosticinterview are excluded. Studies of patients receiving
psychiatric treatment or with psychiatric diagnoses are
excluded with the exception of studies of substance or
alcohol abuse patients. Studies in which only part of
the sample is selected based on distress or depression
may be eligible if data for patients not selected due to
distress levels can be obtained. If only patients above a
cutoff score on the PHQ are administered the diag-
nostic interview, the study is excluded. If, however, a
proportion of patients both above and below the
PHQ cutoff are administered the interview, the study
would be included.
7. Exclude if not adults.
Studies are excluded if it is clear from the title/abstract
that the study sample does not include adults aged 18
and over. Studies with mixed population samples are
eligible for inclusion if data for adults can be obtained.
However, studies that assess only pediatric, adolescent,
school, or undergraduate samples will not be included,
even if some participants are at least 18 years old.
Full-text review
1. Exclude if no original human data or it is a case study.
Exclude if the article is not an original report of pri-
mary data, but for example a letter, editorial, systematic
review or meta-analysis, or it is a case series or single
case study. Studies reporting only on animal, cellular,
or genetic data are also excluded. Studies that report re-
sults in conference abstracts are eligible for inclusion.
2. Exclude if study did not involve administration of
the PHQ-9, PHQ-2, or PHQ-8.
3. Exclude if there is no assessment of major depression.
Exclude if patients were not administered the PHQ-9,
PHQ-2, or PHQ-8. Note that the PHQ-4 (depression
and anxiety) includes the PHQ-2.
Exclude studies if there is not a clinical interview to
diagnose MDD based on DSM or a major depres-
sive episode based on ICD. Studies that include
broader diagnostic categories, such as other depres-
sive (e.g., minor depression, dysthymia) or anxiety
disorders, are eligible for inclusion only if they have
classified adults with MDD or major depressive epi-
sode in the primary data.




Exclude: dysthymic disorder, minor depression (at least
two depressive symptoms are present for 2 weeks)
ICD-10:




STUDY_ID This variable identifies the database that the data
come from, using the primary author or principal
investigator of the original study as the label
1 = Study 1
2 = Study 2
3 = Study 3
4 ….
COUNTRY Country where the study took place
CLINICAL SETTING Clinical setting where the study took place 1 = Primary care
2 = Specialty care
3 = Non-medical setting
DEPRESSD_PT_ID DEPRESSD Registry ID. Sequential numbers from 1 to n
AGE Patient’s age Numerical value
SEX Patient’s sex 1 = Female
2 =Male
999 =Missing
PHQ9_Q1 Patient data for the first PHQ-9 item: Interest/pleasure 0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
999 =Missing
PHQ9_Q2 Patient data for the second PHQ-9 item: Down/depressed/hopeless 0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
999 =Missing
PHQ9_Q3 Patient data for the third PHQ-9 item: Sleep 0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
999 =Missing
PHQ9_Q4 Patient data for the fourth PHQ-9 item: Tired/energy 0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
999 =Missing
PHQ9_Q5 Patient data for the fifth PHQ-9 item: Appetite 0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
999 =Missing
PHQ9_Q6 Patient data for the sixth PHQ-9 item: Feeling bad about self 0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
999 =Missing
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Table 1 Codebook (Continued)
PHQ9_Q7 Patient data for the seventh PHQ-9 item: Concentrating 0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
999 =Missing
PHQ9_Q8 Patient data for the eighth PHQ-9 item: Moving 0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
999 =Missing
PHQ9_Q9 Patient data for the ninth PHQ-9 item: Deaths/hurting self 0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
999 =Missing
PHQ9_Q10 Patient data for final PHQ-9 question: how difficult these problems have
made life
0 = Not difficult at all
1 = Somewhat difficult
2 = Very difficult
3 = Extremely difficult
999 =Missing
PHQ9_TOTAL Total PHQ-9 score (sum of the nine-item scores) 999 =Missing





CLASSIF_SYSTEM Classification system used to classify patients




MDD_DICHOT Major depression diagnostic status 0 = no MDD
1 =MDD
999 =missing
CUR_PSYC_TX Currently receiving psychological treatment
for depression versus not currently receiving
psychological treatment for depression
0 = Not currently receiving psychological
treatment for depression




CUR_PHAR_TX Currently receiving antidepressant medication
versus not currently receiving antidepressant medication
0 = Not currently receiving antidepressant
medication




Thombs et al. Systematic Reviews 2014, 3:124 Page 11 of 16
http://www.systematicreviewsjournal.com/content/3/1/124
Table 1 Codebook (Continued)
CUR_UNSPEC_TX Currently receiving treatment for depression or
not currently receiving treatment for depression
(type of treatment not specified)
0 = Not currently receiving unspecified
treatment for depression




ANY_CUR_TX Currently receiving any kind of treatment
(psychological, pharmacological, or unspecified)
for depression or not currently receiving any
kind of treatment for depression.
0 = Not currently receiving treatment for
depression
1 = Currently receiving treatment for depression
777 = Unknown
999 =Missing




4 = Rheumatic disease
5 = Substance abuse
6 = Other
7 = Multiple
RISK_OF_BIAS_PT_SEL QUADAS-2: Risk of Bias: Patient Selection 1 = Low
2 = Unclear
3 = High
RISK_OF_BIAS_INDEX QUADAS-2: Risk of Bias: Index Test 1 = Low
2 = Unclear
3 = High
RISK_OF_BIAS_REF_STD QUADAS-2: Risk of Bias: Reference Standard 1 = Low
2 = Unclear
3 = High
RISK_OF_BIAS_FLOW QUADAS-2: Risk of Bias: Flow and Timing 1 = Low
2 = Unclear
3 = High
APPLIC_PT_SEL QUADAS-2: Applicability Concerns: Patient Selection 1 = Low
2 = Unclear
3 = High
APPLIC_INDEX QUADAS-2: Applicability Concerns: Index Test 1 = Low
2 = Unclear
3 = High
APPLIC_REF_STD QUADAS-2: Applicability Concerns: Reference Standard 1 = Low
2 = Unclear
3 = High
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a depressive episode with symptomatic criteria, but
lasting less than 2 weeks, and requires that the epi-
sodes occur at least once per month for 12 consecutive
months)Research Diagnostic Criteria (RDC):
Include: major depressive disorder
DSM-III:
Include: major depression
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4. Exclude if studies do not use a validated diagnostic
interview to assess major depression.
Only studies that assess adults for a DSM diagnosis of
MDD or ICD diagnosis of a major depressive episode
using a validated structured or semi-structured diagnos-
tic interview will be included. Examples of validated
diagnostic interviews and other assessment tools that are
not validated diagnostic interviews are listed below.
Studies that clearly only used a self-report questionnaire
to classify patients as depressed are excluded.
Examples of validated diagnostic interviews:
Composite International Diagnostic Interview (CIDI)
Diagnostic Interview Schedule (DIS)
Diagnostic Interview Schedule for Children (DISC)
Diagnostisches Interview bei psychischen Störungen
im Kindes (Kinder-DIPS)
Mini-International Neuropsychiatric Interview (MINI)
Schedule for Affective Disorders and Schizophrenia
(SADS)
Schedules for Clinical Assessment in Neuropsychiatry
(SCAN)
Structured Clinical Interview for DSM (SCID)
Examples of assessment tools that are not validated
diagnostic interviews:
Any self-report measure completed by patients
Hamilton Depression Rating Scale (HAM-D, HDRS)
Montgomery Asberg Depression Rating Scale (MADRS)
Primary Care Evaluation of Mental Disorders
(PRIME-MD)
International Diagnostic Checklist for ICD-10
5. Exclude if PHQ and diagnostic interview are not
administered within 2 weeks of each other.
Studies are excluded if the PHQ and diagnostic interview
were not administered within 2 weeks of one another.
Datasets where some patients were administered the
screening tools within 2 weeks of the diagnostic interview
and some patients were not will be included if the original
data allows us to select patients administered the diagnostic
interview and screening tools within the 2-week window.
6. Exclude if sample selection is based on the presence
of distress or depression.
Studies of patients who are pre-selected as possibly
distressed or depressed (e.g., based on clinician’s judgment
or screening instrument cutoff) prior to administration of
the study screening tool and diagnostic interview are ex-
cluded. Studies of patients receiving psychiatric treatment
or with psychiatric diagnoses are excluded with the ex-
ception of studies of substance or alcohol abuse pa-
tients. Studies in which only part of the sample is
selected based on distress or depression may be eligible
if data for patients not selected due to distress levels
can be obtained. If only patients above a cutoff score
on the PHQ are administered the diagnostic interview, thestudy is excluded. If, however, a proportion of patients
both above and below the PHQ cutoff are administered
the interview, the study would be included.
7. Exclude if not adults.
Studies are excluded if the study sample does not include
adults aged 18 and over. Studies with mixed population
samples are eligible for inclusion if data for adults can be
obtained. However, studies that assess only pediatric,
adolescent, school, or undergraduate samples will not be
included, even if some participants are at least 18 years old.Appendix 3: Preliminary individual patient data
codebook
Instructions for each dataset to be included in the IPD
Database
1. Save the original database as whatever it was called
when it was sent to us and add “(original file)” to
the end.
2. Save a new copy of the database as
AUTHOR_WITH_ID
 In this file, create a new variable called PT_ID.
 If the database already includes a variable with
patient IDs, sort this in ascending order, and
then for the new variable, sequentially number
the patients, starting with the number 1.
 If the database does not already have a variable
with patient IDs, keep the file ordered as is, and
then for the new variable, sequentially number
the patients, starting with the number 1.
3. Save a new copy of the AUTHOR_WITH_ID
database as AUTHOR_IPD.
 In this file, transform, recode, and create new
variables according to the following codebook
(Table 1).
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